179 related articles for article (PubMed ID: 22583468)
1. Reflections: NICE, health economics, and outcomes research.
Rawlins M
Value Health; 2012 May; 15(3):568-9. PubMed ID: 22583468
[No Abstract] [Full Text] [Related]
2. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
Perfetto EM
Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
[No Abstract] [Full Text] [Related]
3. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
Steinbrook R
N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
[No Abstract] [Full Text] [Related]
4. Data briefing. The NICE threshold.
Appleby J
Health Serv J; 2007 Sep; 117(6074):21. PubMed ID: 17970386
[No Abstract] [Full Text] [Related]
5. NICE public health guidance: what's new?
Killoran A; White P; Owen L; Fischer A; Millward L
J Public Health (Oxf); 2009 Mar; 31(1):184-6. PubMed ID: 19153093
[No Abstract] [Full Text] [Related]
6. How should we value future health? Was NICE right to change?
Raftery J
Value Health; 2013; 16(5):699-700. PubMed ID: 23947961
[No Abstract] [Full Text] [Related]
7. Cost-utility analysis: use QALYs only with great caution.
McGregor M
CMAJ; 2003 Feb; 168(4):433-4. PubMed ID: 12591784
[No Abstract] [Full Text] [Related]
8. Health economics: a beginner's guide.
Thornton JG
Br J Hosp Med; 1997 Dec; 58(11):547-50. PubMed ID: 10193467
[TBL] [Abstract][Full Text] [Related]
9. Health economics. A bridge over troubled water.
Brouwer WB; Rutten FF
Eur J Public Health; 2001 Jun; 11(2):234-6. PubMed ID: 11420818
[No Abstract] [Full Text] [Related]
10. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
Sculpher M
Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness considerations at NICE.
Rawlins M; Dillon A
Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903
[No Abstract] [Full Text] [Related]
12. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
[TBL] [Abstract][Full Text] [Related]
13. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
Solow B; Pezalla EJ
Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
[No Abstract] [Full Text] [Related]
14. Should the NHS strive to eradicate all unexplained variation? Yes.
Richards S
BMJ; 2009 Nov; 339():b4811. PubMed ID: 19926690
[No Abstract] [Full Text] [Related]
15. Health economics and nursing management.
Newbold D
J Nurs Manag; 2005 Sep; 13(5):373-6. PubMed ID: 16108774
[No Abstract] [Full Text] [Related]
16. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
Burkholder R; Dougherty JS; Neves LA
Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
[No Abstract] [Full Text] [Related]
17. Is economic evaluation in touch with society's health values?
Coast J
BMJ; 2004 Nov; 329(7476):1233-6. PubMed ID: 15550430
[TBL] [Abstract][Full Text] [Related]
18. The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents.
Firth BG; Cooper LM; Fearn S
Health Aff (Millwood); 2008; 27(6):1577-86. PubMed ID: 18997214
[TBL] [Abstract][Full Text] [Related]
19. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of health interventions.
Drummond M; Weatherly H; Ferguson B
BMJ; 2008 Sep; 337():a1204. PubMed ID: 18824485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
